Investment Rating - The overall industry investment rating is neutral, indicating that the expected return over the next six months is between -5% and 5% relative to the CSI 300 index [9]. Core Insights - The pharmaceutical sector experienced a gain of 1.04% on April 14, 2025, outperforming the CSI 300 index by 0.81 percentage points, ranking 18th among 31 sub-industries in the Shenwan classification [4]. - The approval of Kowa's Pemafibrate in China for treating dyslipidemia is a significant development, as it is a novel PPARα agonist that lowers triglyceride levels and increases HDL-C levels [5]. - Notable stock performances included YK Pharma (+19.99%), Yipinhong (+19.30%), and Kexing Pharma (+16.83%), while Haizhi Science (-4.28%), Yirui Technology (-3.71%), and Huada Manufacturing (-3.48%) saw declines [4]. Sub-industry Summary - Chemical Pharmaceuticals: No rating [3] - Traditional Chinese Medicine: No rating [3] - Biopharmaceuticals II: Neutral [3] - Other Pharmaceutical Industries: Neutral [3]
太平洋医药日报：Kowa佩玛贝特片在华获批上市
Tai Ping Yang·2025-04-15 09:30